Sign in
Active, not recruitingNo phase

Transcriptional and Epigenetic Program of PCOS Women

Key facts

Who runs it
AdventHealth Translational Research Institute
Where
Orlando, United StatesSee the site
Trial code
Status
Active, not recruiting
People taking part
108 people enrolled
Started
31 Jan 2020
Ended
Dec 2025
Type of study
Observational, 2 groups
Treatments tested
  • DEXA
  • Magnetic Resonance (MR) Assessment of the Abdomen
  • MR assessment of Whole Body Fat
  • Adipose tissue biopsy
  • Oral glucose tolerance test
Record updated
13 March 2025

Who can take part

Age
18 years to 45 years
Sex
Women only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 37 criteriaShow less

Who can take part

  • Women
  • Age 18-45 years inclusive
  • BMI 23-40 kg/m2 inclusive
  • HbA1C ≤ 6.0% or fasting plasma glucose < 126 mg/dL
  • Weight stable (± 3 kg) during the 3 months prior to enrollment
  • Women must be > 9 months post-partum
  • For PCOS: A documented history of PCOS from their physician according to the Androgen Excess (AE)-PCOS criteria: (defined by the presence of hyperandrogenism (clinical and/or biochemical), ovarian dysfunction (oligo-anovulation and/or polycystic ovaries), and the exclusion of related disorders (eg. hypoadrenalism, ovarian tumors)
  • Regular menstrual cycle for females without PCOS
  • Able to provide written, informed consent

Who cannot take part

  • Use of any medications known to influence fat and/or energy metabolism (eg growth hormone therapy, glucocorticoids [steroids], etc.)
  • Initiation or change in hormone replacement therapy within the past 3 months (including, but not limited to thyroid hormone, estrogen replacement therapy or In Vitro Fertilization therapy)
  • Current treatment with blood thinners or antiplatelet medications that cannot be safely stopped for biopsy and testing procedures
  • Not able to participate in MRI assessments due to:; Metal implants (pacemaker, non-removable body piercings, aneurysm clips) based on Investigator's judgment at screening; Physical limitations or equipment tolerances (e.g., MRI bore size) based on Investigator's judgment at screening; Inability to tolerate MRI imaging without sedation or claustrophobia
  • History or presence of cardiovascular disease (unstable angina, myocardial infarction or coronary revascularization within 6 months, clinically significant abnormalities on EKG), presence of cardiac pacemaker, implanted cardiac defibrillator
  • Uncontrolled hypertension (BP >160 mmHg systolic or >100 mmHg diastolic)
  • Elevated hsCRP or known active infection
  • History of cancer within the last 5 years (skin cancers, with the exception of melanoma, may be acceptable)
  • History of drug or alcohol abuse (> 3 drinks per day) within the last 5 years. Current drug use may be determined by plasma or urine drug screens
  • psychiatric disease prohibiting adherence to study protocol
  • History of organ transplant
  • Known history of HIV, active Hepatitis A, B or C or tuberculosis
  • History of bariatric surgery
  • Presence of any condition that, in the opinion of the Investigators, compromises participant safety or data integrity or the participant's ability to complete study visits
  • Fasting plasma glucose > 126 mg/dL, or HbA1c > 6% or diagnosis with Type 2 Diabetes (T2D) or Type 1 Diabetes (T1D)
  • Liver disease (AST or ALT >2.5 times the upper limit of normal)
  • Kidney disease (creatinine >1.6 mg/dl or estimated GFR <60 ml/min)
  • Dyslipidemia, including triglycerides >500 mg/dl, LDL >200 mg/dl
  • Anemia (hemoglobin <11 g/dl)
  • Use of oral or injectable anti-hyperglycemic agents: metformin, sulfonylureas, DPP IV inhibitors, SGLT-2 inhibitors, thiazolidinediones, acarbose, GLP-1 analogs and insulin unless willing to undertake a washout period of 15 days for metformin and GLP-1 analogs and undergo subsequent laboratory screening tests
  • Postmenopausal women
  • Women with hysterectomy
  • Pregnancy, lactation or < 9 months postpartum from the scheduled date of screening
  • Thyroid dysfunction (suppressed thyroid-stimulating hormone, elevated TSH <10 µIU/ml if symptomatic or elevated TSH >10 µIU/ml if asymptomatic)
  • Current smokers (smoking within the past 3 months)
  • Current use of beta-adrenergic blocking agents
  • Gonadotropin Releasing Hormone (GnRH) and/or Antiandrogen use within the last 2 months
  • Not able or willing to have DXA scans or are above the acceptable weight limit (450 lbs) of the DXA scanner

Where in United States

  • AdventHealth Translational Research InstituteOrlando, United States

About the trial

What the trial wants to find out

The main goal is to reveal differences in global gene expression in two different adipose tissue (AT) depots of females with and without polycystic ovary syndrome (PCOS) and how these are influenced by upstream epigenetic markers

The 2 groups in the trial

  • PCOS females

    Females diagnosed with PCOS with a BMI between 23 and 40 kg/m2.

    Treatment: DEXA, Magnetic Resonance (MR) Assessment of the Abdomen, MR assessment of Whole Body Fat, Adipose tissue biopsy, and Oral glucose tolerance test

  • Non-PCOS control females

    Females without PCOS with a BMI between 23 and 40 kg/m2 split into 2 groups- apple shaped and pear shaped.

    Treatment: DEXA, Magnetic Resonance (MR) Assessment of the Abdomen, MR assessment of Whole Body Fat, Adipose tissue biopsy, and Oral glucose tolerance test

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
13 March 2025